SC
MNPR icon

Steven Cohen’s Monopar Therapeutics MNPR Stock Holding History

Steven Cohen’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104,019
Closed -$3.72M – 2544
2025
Q2 		$3.72M Sell
104,019
-64,141
-38% -$2.33M 0.01% 1066
2025
Q1 		$6.12M Buy
168,160
+268
+0.2% +$9.66K 0.01% 853
2024
Q4 		$3.69M Buy
+167,892
New +$2.82M 0.01% 1039

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Steven Cohen's MNPR Position: Q3 2025 in Review

Steven Cohen sold out of Monopar Therapeutics (MNPR) in Q3 2025, closing a stake of 104,019 shares — an estimated $3.72M sold.

Steven Cohen first reported a position in MNPR in Q4 2024 and held it in 3 quarters. The position peaked at $6.12M in Q1 2025. 56 funds tracked by Wall St. Rank hold MNPR as of Q3 2025.

  • Steven Cohen reported no remaining Monopar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Steven Cohen sold 104,019 Monopar Therapeutics shares in Q3 2025, an estimated $3.72M.
  • Steven Cohen first reported a position in Monopar Therapeutics in Q4 2024 and held it in 3 quarters.
  • Steven Cohen's Monopar Therapeutics position peaked at $6.12M in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.